Lonza's MODA-EM Paperless Solution to Be Implemented at the UK's New Vaccines Manufacturing and Innovation Centre
Basel, Switzerland and Harwell, UK, 07 December 2020 – Lonza and the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK’s first strategic vaccine development and advanced manufacturing capability, announced a project to implement the MODA-EM™ Solution to automate quality control (QC) in the new facility.
VMIC plans to implement the MODA-EM™ Solution as part of its strategy to develop a state-of- the-art manufacturing center due to open in 2021 – fast-tracked to open a year ahead of schedule. The MODA-EM™ Solution is a comprehensive informatics platform that automates QC processes for regulated manufacturing in the Life Sciencesindustry. This fully digital QC system enables companies to reduce the time needed for validation and qualification and provides a forward- thinking paperless solution.
The ongoing COVID-19 pandemic has accelerated multiple industry trends, including digitalization and automation. Implementing paperless solutions can help researchers meet aggressive timelines and fit into Industry 4.0 initiatives. Lonza’s comprehensive, next- generation solution for pharmaceutical QC will allow paperless management of a wealth of microbiological data. The electronic approach reinforces data integrity compliance, enables real-time access to data, and provides fast input necessary to make informed decisions.
The automation of the QC laboratory has seen slow adoption by organizations due to cost constraints and flexibility concerns. The MODA-EM™ Data Acquisition Platform for automated and paperless QC processes is changing this, thanks to the ease of implementation to achieve regulatory compliance and maximize employee utilization.
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.
Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.
Lonza Contact Details
Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel 41 61 316 8929
Lonza Group Ltd
Tel 41 79 421 1609
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.